Equities

Nova Leap Health Corp

NLH:CVE

Nova Leap Health Corp

Actions
FinancialsOpen End and Miscellaneous Investment Vehicles
  • Price (CAD)0.24
  • Today's Change0.00 / 0.00%
  • Shares traded2.80k
  • 1 Year change+33.33%
  • Beta1.5307
Data delayed at least 15 minutes, as of Sep 19 2024 18:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in CAD

The one analyst offering a 12 month price target expects Nova Leap Health Corp share price to rise to 0.600 in the next year from the last price of 0.24.
High150.0%0.600
Med150.0%0.600
Low150.0%0.600

Earnings history & estimates in CAD

On May 09, 2024, Nova Leap Health Corp reported 1st quarter 2024 earnings of 0.005 per share. This result was in line with the expectation of the one analyst following the company and outperformed last year's 1st quarter results by 0.008.
The next earnings announcement is expected on Nov 07, 2024.
Nova Leap Health Corp reported annual 2023 losses of -0.012 per share on Mar 07, 2024.
Average growth rate-20.00%
More ▼

Revenue history & estimates in CAD

of 8.92m. This missed the 11.49m estimate of the one analyst following the company.
Average growth rate+8.18%
Nova Leap Health Corp. had revenues for the full year 2023 of 35.33m. This was 25.27% above the prior year's results.
Average growth rate+28.83%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.